Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
复制标题

DOI:
10.1016/j.leukres.2008.11.024
复制
发表时间:
2009-09
期刊:
影响因子:
2.7
通讯作者:
Klingemann H
Klingemann H
中科院分区:
医学3区
文献类型:
--
作者:
Boissel L;Betancur M;Wels WS;Tuncer H;Klingemann H

文献摘要

参考文献

被引文献

相似文献

慢性淋巴细胞白血病(CLL)的一种新兴治疗选择是使细胞毒性免疫细胞表达识别CLL细胞上特异性表面分子的嵌合抗原受体(CAR)。在此,通过电穿孔将编码抗CD 19 CAR的mRNA转染到NK-92细胞系中。与cDNA相反,mRNA导致高转染效率(47.2 ± 8%,而cDNA <5%),对细胞活力的影响最小。表达抗CD 19 CAR的NK-92细胞杀死先前耐药的CD 19 + BALL细胞系以及原代CLL细胞,因此可能为CLL患者提供安全的、基于细胞的靶向治疗。
An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 ± 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ BALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.
DOI: 10.1056/nejm200012143432402
发表时间: 2000-12-14
影响因子: 158.5
作者:
Rai, KR;Peterson, BL;Schiffer, CA
通讯作者: Schiffer, CA
DOI: 10.1089/hum.2006.17.1027
发表时间: 2006-10-01
期刊: HUMAN GENE THERAPY
影响因子: 4.2
作者:
Rabinovich, Peter M.;Komarovskaya, Marina E.;Weissman, Sherman M.
通讯作者: Weissman, Sherman M.
DOI: 10.1200/jco.2007.12.9098
发表时间: 2007-12-10
影响因子: 45.3
作者:
Hillmen, Peter;Skotnicki, Aleksander B.;Mayer, Jiri
通讯作者: Mayer, Jiri
DOI: 10.1016/j.suronc.2007.10.043
发表时间: 2007-12-01
影响因子: 2.3
作者:
Moretta, Lorenzo
通讯作者: Moretta, Lorenzo